Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 11/20 | 0.59 |
| ▸ | HBB | P68871 | 2/20 | 0.59 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | EDNRA | P25101 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HPRT1 | P00492 | 3/20 | 0.55 |
| ▸ | POLG | P54098 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630850 | 0.94 | PNP (0.67) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL29370760 | 0.79 | PNP (0.87) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL7814355 | 0.79 | MEN1 (0.76) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL11244147 | 0.78 | MEN1 (0.71) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL14501172 | 0.78 | PNP (0.73) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL14501075 | 0.78 | PNP (0.73) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL631990 | 0.78 | MEN1 (0.58) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL8842958 | 0.77 | PNP (0.69) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL1685246 | 0.77 | MEN1 (0.44) | PNPHBBBLMTSHRUSP2 | |
| SCHEMBL12088904 | 0.77 | PNP (0.71) | PNPHBBBLMTSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891071-B1 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | claimed |
| US-7846937-B2 | Cyclopropanecarboxylate esters of acyclovir | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | claimed |
| US-20090270428-A1 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | ELI LILLY AND COMPANY | 2009-10-29 | — | — | US | claimed |
| EP-1891071-A2 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | ELI LILLY AND COMPANY (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006127217-A2 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | ELI LILLY AND COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| US-8853222-B2 | Treatment of herpes virus related diseases | EXLEY RAY W (US) | 2014-10-07 | — | — | US | disclosed |
| EP-1891071-B1 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20110112117-A1 | TREATMENT OF HERPES VIRUS RELATED DISEASES | EXLEY RAY W | 2011-05-12 | — | — | US | disclosed |
| EP-2257294-A2 | TREATMENT OF HERPES VIRUS RELATED DISEASES | Exley, Ray W. (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7846937-B2 | Cyclopropanecarboxylate esters of acyclovir | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090270428-A1 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | ELI LILLY AND COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009111739-A2 | TREATMENT OF HERPES VIRUS RELATED DISEASES | EXLEY RAY W (US) | 2009-09-11 | — | — | WO | disclosed |
| EP-1891071-A2 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | ELI LILLY AND COMPANY (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006127217-A2 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | ELI LILLY AND COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112117-A1 | TREATMENT OF HERPES VIRUS RELATED DISEASES | TPMT, METAP2, DNPEP | PNP 82/4885HBB 4014/4885BLM 4459/4885 |
| US-20090270428-A1 | CYCLOPROPANECARBOXYLATE ESTERS OF ACYCLOVIR | TYMP, PAICS, IMPDH1 | PNP 7/4885HBB 2483/4885BLM 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.